

IND SAFETY REPORT: INITIAL WRITTEN REPORT**TO: Division of Biologic Oncology Products, Center for Drug Evaluation and Research, FDA****FAX: 301-796-9849**

1. IND NUMBER

7921

2. AGENT NAME

Bevacizumab (rhuMAb VEGF)

3. DATE

April 29, 2009

4. SPONSOR

Division of Cancer Treatment and Diagnosis, National Cancer Institute

5. REPORTER=S NAME, TITLE, AND INSTITUTION

**Helen Chen, MD-Associate Branch Chief for Investigational Therapeutics
3, CTEP, DCTD, NCI**

6. PHONE NUMBER

301-496-1196

7. FAX NUMBER

301-402-0428

8. PROTOCOL NUMBER (AE #)

E1505 (AE # 1133874)

9. PATIENT IDENTIFICATION

15229

10. AGE

68

11. SEX

Male

12. DESCRIPTION OF ADVERSE EVENT

The patient is a 68-year-old male with a non-small cell lung cancer, who experienced grade 4 thrombocytopenia while on phase 3 study utilizing the investigational agent bevacizumab in combination with cisplatin and gemcitabine. He began his first course of treatment on October 13, 2008, and received his last dose of bevacizumab on February 9, 2009 (Cycle 7, Day 1). His last doses of cisplatin and gemcitabine were on December 8, 2008 (Cycle 3, Day 15) and December 15, 2008 (Cycle 4, Day 1), respectively. On March 2, 2009, the patient presented for Cycle 8, Day 1, when a CBC showed severe thrombocytopenia with a platelet count of 4 K/ μ L. Another blood sample showed a platelet count of 7 K/ μ L, and the patient was subsequently admitted to the hospital for emergent treatment. During admission, he was treated with intravenous Solumedrol[®], oral prednisone, and immune globulin. On March 5, 2009, his platelet count was 18 K/ μ L. On March 6, 2009, the patient had a platelet count of 25 K/ μ L, and he was subsequently discharged from the hospital. The investigational agent was withheld. Additional information has been requested from the investigational site. There is a reasonable possibility that the experience may have been caused by the drug.

13. DOSE, ROUTE, AND SCHEDULE **Cycle = 21 days****Bevacizumab 15 mg/kg IV over 30-90 minutes on Day 1 (Cycles 1-4);****Bevacizumab 15 mg/kg IV over 30-90 minutes on Day 1 every 3 weeks, for up to 1 year.**14. DATES OF TREATMENT **The patient started the investigational therapy on October 13, 2008, and received the last dose of bevacizumab on February 9, 2009 (Cycle 7, Day 1).**15. ACCRUAL AND IND EXPERIENCE **Number of patients enrolled in NCI-sponsored clinical trials using bevacizumab = 20511. There have been 69 other incidences of thrombocytopenia reported to the NCI through AdEERS as serious adverse events for bevacizumab.**16. COMMENTS **The following was also administered:****Cisplatin: 75 mg/m² IV over 60 min on Day 1 (last administered on December 8, 2008).****Gemcitabine: 1200 mg/m²/day IV over 30 min on Days 1 and 8 (last administered on December 15, 2008).****AT THIS TIME, NO OTHER INFORMATION IS AVAILABLE. IF UPON FURTHER INVESTIGATION RELEVANT INFORMATION BECOMES AVAILABLE, THEN A FOLLOW-UP REPORT WILL BE SUBMITTED IN ACCORDANCE WITH 21CFR 312.32(d)(2).****DISCLAIMER per 21 CFR 312.32(e): THIS SAFETY REPORT DOES NOT NECESSARILY REFLECT A CONCLUSION OR ADMISSION BY THE CTEP IDB SENIOR INVESTIGATOR/ SPONSOR THAT THE INVESTIGATIONAL AGENT/THERAPY CAUSED OR CONTRIBUTED TO THE ADVERSE EXPERIENCE BEING REPORTED.**

0002